T
BCRX icon

TCWP’s BioCryst Pharmaceuticals BCRX Stock Holding History

TCWP’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-13,500
Closed -$95.6K – 59
2023
Q3 		$95.6K Hold
13,500
– – 0.07% 103
2023
Q2 		$95K Buy
13,500
+3,500
+35% +$28.1K 0.02% 178
2023
Q1 		$83.4K Hold
10,000
– – 0.02% 244
2022
Q4 		$115K Hold
10,000
– – 0.02% 247
2022
Q3 		$126K Hold
10,000
– – 0.03% 261
2022
Q2 		$105K Hold
10,000
– – 0.02% 259
2022
Q1 		$162K Hold
10,000
– – 0.03% 283
2021
Q4 		$138K Buy
+10,000
New +$132K 0.03% 255

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TCWP's BCRX Position: Q4 2023 in Review

TCWP sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2023, closing a stake of 13,500 shares — an estimated $95.6K sold.

TCWP first reported a position in BCRX in Q4 2021 and held it in 8 quarters. The position peaked at $162K in Q1 2022. 235 funds tracked by Wall St. Rank hold BCRX as of Q4 2023.

  • TCWP reported no remaining BioCryst Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • TCWP sold 13,500 BioCryst Pharmaceuticals shares in Q4 2023, an estimated $95.6K.
  • TCWP first reported a position in BioCryst Pharmaceuticals in Q4 2021 and held it in 8 quarters.
  • TCWP's BioCryst Pharmaceuticals position peaked at $162K in Q1 2022.
  • 235 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2023.

Based on TCWP's 13F filing for Q4 2023, filed 14 Feb 2024.